10 Best Short-Term Stocks To Buy Right Now

2. Acelyrin, Inc. (NASDAQ:SLRN)

Last 52 weeks return: -65.06%

Last 1 month’s return: 29.11%

No. of hedge fund portfolios: 28

Acelyrin, Inc. (NASDAQ:SLRN) is a biotechnology firm headquartered in California, the U.S., and engaged in developing immunology-focused therapies for treating chronic inflammatory diseases. The company’s pipeline includes treatments targeting autoimmune conditions such as hidradenitis suppurativa and inflammatory arthritis. Specifically, the company focuses on advancing biologics with novel mechanisms of action, thus acquiring a position in next-generation immunotherapy.

Acelyrin, Inc. (NASDAQ:SLRN) has endured a 65.06% decline over the last 52 weeks. In late 2023, the company raised $540 million in a rare biotech IPO. It reported the failure of this lead prospect in a phase 2b/3 inflammatory disease clinical trial. The result was a sharp decline in the company’s share price during the initial quarters of 2024. Later, the company reported positive Phase II data for its monoclonal antibody lonigutamab in thyroid eye disease (TED), but it failed to meet the investors’ expectations.

The recent momentum, however, has been encouraging. Acelyrin, Inc. (NASDAQ:SLRN) has gained 29.11% in the past month. The rise comes after receiving an unsolicited indication of interest from Concentra Biosciences. Concentra offered $3 per share plus Contingent Value Right (CVR). However, Acelyrin’s board of directors determined to turn it down, claiming that this offer was not reasonably expected to result in a superior proposal compared to the planned merger with Alumis. The reaffirmation, as reflected by the rise in stock price, contributed to investor optimism. The 20-day SMA increases by 8.47% while the 200-day SMA is at -35.33%.

Backed by 28 hedge fund portfolios from the Insider Monkey Q4 2024 database, Acelyrin, Inc. (NASDAQ:SLRN) has attracted significant institutional interest, making it a candidate for those seeking short-term stocks amid market fluctuations.